Women’s History Month: Amy Reed, Carol Fabian

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Women’s History Month

Reed, an anesthesiologist, became the face of a national campaign against power morcellation  after she underwent the procedure at Brigham & Women’s Hospital. Her advocacy saved the lives of many women.

I always wanted to be a doctor when I was little. I wanted to go into medicine and be a doctor and fix things, and cure the world

Amy Reed

Weeks after her “minimally invasive” surgery in 2013, Reed learned that the spinning blades of the morcellator contributed to the spread of an undiagnosed aggressive uterine cancer, leiomyosarcoma, throughout her abdominal cavity.

She wasn’t the first. Erika Kaitz, another woman in Boston, had died from disseminated cancer at the same hospital in 2013. Reed and her husband, Hooman Noorchashm, were the first to publicly make the connection. Hundreds of women have since come forward claiming to have been similarly harmed.

Reed died May 24, 2017, less than four years after her surgery. She was 44. Reed and Noorchashm’s relentless campaign sparked multiple investigations, and changed the standard of care in minimally invasive gynecology.

Reed’s legacy continues to influence the regulation of surgical medical devices and reshape the way gynecologists assess cancer risk and prevalence. The Cancer Letter’s award-winning coverage of her war against morcellation tracks each development—changes in FDA’s guidances, device recalls, litigation, and Congressional hearings (The Cancer LetterHow Medical Devices Do Harm, 2014-2017).

More studies over the years show how cancers are frequently missed prior to routine minimally invasive procedures—signaling a need for more robust preoperative work-up to identify at-risk women, as well as more rigorous evaluation of innovative surgical procedures, including robotic surgery.

The Cancer Letter’s investigation continues (When Surgical Innovation Kills, 2018-present).


Recent contributions


This column in The Cancer Letter features the latest posts to the Cancer History Project by our growing list of contributors.

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj.


Is your institution a contributor to the Cancer History Project? Would you like us to tell you about the project and how you can get involved?

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more
The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.
The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login